Tag: @WeillCornell

Patients Who Stopped Tirzepatide (Mounjaro™) For Weight Control Gradually Regained Most of Lost Weight 

Obesity is a chronic disease, like diabetes and hypertension. If treatment is discontinued, it will relapse, though gradually.

WeightControl.com Interview with:
Louis J Aronne M.D.
Sanford I. Weill Professor of Metabolic Research
Department of Medicine
Weill Cornell Medicine

WeightControl.com:  What is the background for this study? What are the main findings?

Response: The SURMOUNT -4 trial demonstrates that patients who discontinued tirzepatide after losing 20.9% over 36 weeks regained about half the weight in one year to an average 9.5% weight loss following discontinuation while those who continued lost an additional 5%.  

The metabolic parameters which had improved with weight loss returned towards their starting point, but did not completely regress.  

Continue reading “Patients Who Stopped Tirzepatide (Mounjaro™) For Weight Control Gradually Regained Most of Lost Weight “